Trial Profile
A Multi-Center, Open-Label, Randomized, Parallel Group, Dose-Ranging, Pharmacodynamic Phase II Trial to Determine the Effects of Bardoxolone Methyl (RTA 402, Amorphous Dispersion) on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease (eGFR 15-45 mL/Min/1.73m2)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Feb 2024
Price :
$35
*
At a glance
- Drugs Bardoxolone methyl (Primary)
- Indications Renal failure; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Reata Pharmaceuticals
- 14 Nov 2016 Results published in the Reata Pharmaceuticals Media Release
- 19 Dec 2014 New trial record